Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)

Next Previous
Trial Profile

A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 10 Dec 2024 Results (n=66) evaluating the safety and efficacy of the triple combination of Quizartinib (Quiz), VEN, and decitabine (DAC) in pts with relapsed/refractory (R/R) or newly diagnosed FLT3-ITD m AML presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 16 Apr 2024 Planned number of patients changed from 72 to 73.
  • 07 Feb 2024 Planned number of patients changed from 52 to 72.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top